Invasive Heart Pressure Study in People With Valve Disease
Compares invasive heart pumping measurements with imaging-based estimates in adults with valvular heart disease.
Plain-language title generated from the registry record
Registry title: Pressure-Volume Loop Assessment in Valvular Heart Disease
Key facts
- Where
- Nantes, FranceSee the site
Where in France
- CHU of NantesNantes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07112391
- Record updated
- 16 September 2025
- Original description
The VHD PV loop study intends to assess invasive right ventricular to pulmonary artery (RV-PA) coupling in patients with valvular heart disease (VHD). Invasive RV-PA coupling is measured by using conductance catheters, the gold standard assessment for ventricular physiology. Several non-invasive parameters have been reported as surrogates for this complex physiological entity, but none of them has been tested against the gold-standard in this population. Based on this, our main objective is to assess the correlation of imaging derived RV-PA coupling in comparison to the invasive measurement.Read full original descriptionShow less
Invasive Hemodynamic Study of Structural Heart Diseases: A Monocentric, Non-Randomized Approach
The VHD PV loop study intends to assess invasive right ventricular to pulmonary artery (RV-PA) coupling in patients with valvular heart disease (VHD). Invasive RV-PA coupling is measured by using conductance catheters, the gold standard assessment for ventricular physiology. Several non-invasive parameters have been reported as surrogates for this complex physiological entity, but none of them has been tested against the gold-standard in this population. Based on this, our main objective is to assess the correlation of imaging derived RV-PA coupling in comparison to the invasive measurement.
Inclusion: Adult patients (≥ 18 years old); Patients with severe structural heart disease (meeting at least one of the following three criteria):; Heart failure with moderate-to-severe or severe secondary mitral regurgitation; At least severe tricuspid regurgitation; Significant pulmonary valve stenosis and/or regurgitation.
Exclusion: Contraindication to right heart catheterization, including:; Known proximal venous occlusion of the superior or inferior vena cava territory; Presence of a mobile mass in the right heart chambers; Significant tricuspid stenosis; Patients under legal guardianship or protection (e.g., guardianship, trusteeship, or any other legal protection measure); Pregnant or breastfeeding women; Vulnerable individuals (e.g., persons deprived of liberty, adults under legal protection).